ndence is being deposited with the United States Postal Service on the date set forth below as First Class p envelope addressed to: Mail Stop Amendment, Commissioner for Pacents, P Q Box 1450, Alexandria, VA 22313-1450.

ture and Deposit: January 22, 2007

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Alfred W. Widmer, et al.

Date: January 22, 2007

Serial No.: 10/579.263

Art Unit: --

Filing Date: May 12, 2006

Examiner: --

Title: BIS-CATIONIC COMPOUNDS

File No.: 920993.00002

AND USE THEREOF

Confirmation No.: --

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P O Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed are completed forms PTO/SB/08a and PTO/SB/08b, listing documents that Applicants wish to bring to the attention of the Examiner for consideration in connection with the examination on the merits of the above-identified application. The following are submitted in compliance with 37 C.F.R. §§ 1.97-1.98 and in accordance with 37 C.F.R. § 1.97(b). Where appropriate, copies of the necessary documents are enclosed in compliance with 37 C.F.R. § 1.98(a)(2).

The information listed in the accompanying forms PTO/SB/08a and PTO/SB/08b and provided herewith may be material to the above-identified application and is submitted in compliance with the requirements of 37 C.F.R. §1.56.

In compliance with the requirement of 37 C.F.R. §1.98(a)(3)(i), foreign document JP 2000/313171 is included in the information disclosure statement because it discloses quaternary ammonium or quaternary phosphonium derivates used in reversible, heat-sensitive recording material.

Fees

TEL (608) 251-5000

FAX (608) 251-9166

No fee is believed due in connection with this submission. However, if a fee is due, please charge the fee to Deposit Account No. 17-0055.

Respectfully submitted,

Bennett J. Berson Reg. No. 37,094

Attorney for Applicants
QUARLES & BRADY LLP

P.O. Box 2113

Madison, WI 53701-2113

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ersons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known

Application Number 10/579,263

Attorney Docket Number 920993.00002

May 12, 2006 Filing Date First Named Inventor Alfred W. Widmer Examiner Name

(Use as many sheets as necessary)

Sheet 1

			U. S. PATEN	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan
		Number-Kind Code ² (F Assess)			Figures Appear
		^{US-} 6,096,788	08-01-2000	Vial et al.	
		US-			
-	_	US-			
		US-			1
		US-			
		US-			
		US-			
-		US-	1		
		US-			
		US-			
	_	US-			
		US-	_		
		US-	1		
		US-			
	l -	ÚS-	1		

Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Peges, Columns, Lines, Where Relevant Pessages Or Relevant Figures Appear	Τ.
		Country Code ³ "Number ⁴ "Kind Code ⁶ (if Known)	MM-DD-YYYY			T°
		EP 0,494,613 A2	07-15-1992	Saiki		
		JP 2000/313171 (English	11-14-2000	Atsushi & Kenichi		
		abstract provided)				L
		WO 98/04252	02-05-1998	Vial et al.		
						L

12/14/2009 /Binta Robinson/ Considered Signature

**EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation from in conformance and not considered, include copy of this from with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kind Codes of USPTO Pearto Downments at www.septogo.gov or MPEP 90.0 ob. *Einer Office that issued the decouriers, by the two-lefter code (WPE) Standard's 73.1, *For Japanese patient documents, by the two-lefter code (WPE) Standard's 73.1, *For Japanese patient documents, by the two-lefter code (WPE) Standard's 73.1, *For Japanese patient source of the patient document. *Kind of document with the appropriate symbols as indicated on the document under WPE) Standard's 71.5 if possible. *Applicant is to place a cached many free if English linguage

Transition is statched.

Transiderion in demonstron is required by 37 CFR 1.97 and 1.98. The information is required to death or retain a breefit by the public which is to fire fund by the solicity of the property of the p

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (07-05)

Approved for use through DY3 (2000).

U.S. Petern and Transferant Officer. U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO Application Number 10/579,263 Filing Date INFORMATION DISCLOSURE May 12, 2006 STATEMENT BY APPLICANT First Named Inventor Alfred W. Widmer Art Unit (Use as many sheets as necessary) Examiner Name Sheet 2 Attorney Docket Number 920993.00002 of

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issu number(s), publisher, city and/or country where published.			
		Anclein M, et al., "Potent inhibitors of Plasmacions, sgents chemother 2003 metabolism with a broad spectrum of in vitro 47:2590-2597			
		antimatariat/activities;//>AntimicrobxAgents:Chemother.v47x2590v2597x (2998)x			
		Ancelin M, et al., "In vivo antimalarial activities of mono- and bis quaternary ammonium salts interfering with 147,2598-2605 (2003).			
		Plasmodium phospholipid metabolism,7-AntimicrobAgents: Ohemotherx 47:2598-2605.(2003).xx			
		Calas M, et al., "Antimalarial activity of molecules interfering with Plasmodium falciparum phospholipid metabolism." https://doi.org/1997			
		Structure-activity/relationship analysis;**3**Med:*Chem;*40;3557/3566***********(4997);xxx	xxx		
		Ganendren R, et al., "In vitro antifungal activities of inhibitors of phospholipases from the fungal pathogen hatimicrob. Agents Chemother. 43	:1561		
		Cryptococcus neoformans; Antimicrob: Agents Chemother: 48:4561:4569: (2004)::::X			

Examiner	/Binta Robinson/	Date	12/14/2009
Signature	/BIRICA HODINSON/	Considered	12/14/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2 annotated by H Reese 02/08/2011

^{*}EXAMINE: Initial inferience considered, whether or not citation is in conformance with MPEP 099. Draw line through claim in froit in conformance and not considered, include copy of this form with next communication to applicant.

Lappicant's unique culation designation number (polipical) 2 Appicant is not provided a crick, make here | English improves for resistant is instantial.

Lappicant's unique culation designation number (polipical) 2 Appicant is not prequired to obtain or retains is hereful by the public which is to list land by the USPTO process) are application. Confidentiality in governed by 33 U.S. 1.22 and 37 CFR 11.4. This colorion is estimated to late 2 hours to commiste, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any commental community control of the provided to complete in form and/or supposessors for reducing this border, should be sent to the Chief Information Officer, U.S. Patient and Trademirk Officer, P.O. Box 14(3), Alexandrius, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 14(3), Alexandrius, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Approved for use through 07/31/2006. OMB 0651-0031 rademark Office; U.S. DEPARTMENT OF COMMERCE

Un	er the Paperwork Re-	duction A	ct of 1995, no persons ar	e required to respond to a collection	of information unless it contains a valid OMB control number. Complete if Known
Substitu	te for form 1449/PTO			Application Number	10/579,263
INF	ORMATION	N DIS	CLOSURE	Filing Date	May 12, 2006
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Alfred W. Widmer
				Art Unit	
	(Use as many sh	eets as n	ecessary)	Examiner Name	
Sheet	3	of	3	Attorney Docket Nurnber	920993.00002

NON PATENT LITERATURE DOCUMENTS Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of					
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
HLR 2/8/2011		Chemical Abstract 123:180319 1997			
HLR		Chemical Abstract 129:294300 1998			
HLR		Chemical Abstract 132:116550 1999			
HLR		Chemical Abstract 91:101848 1979			
HLR		Chemical Abstract 130:38597 1998			
HLR		Chemical Abstract 132:231503 2000			
	- 10				

Examiner	/Binta Robinson/	Date	12/14/2009
Signature	/Dirita Hobilisons	Considered	12/14/2005

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2. annotated by HReese 02/08/2011

considered, Include copy of this form with next communication to applicant.

1 Applicant's unjust calcidant designation unturble (optional). 2 Applicant is to be place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 198. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is operated by 38 US C 12 and 27 CFR 11.4. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of their your require to complete the form and/or supegestions for reducing this burdent, should be sent to the Chef information Officer. IV. S. Potent and Tragelman Citics, P.O. Box 1450, Absardalo, 22215 1469. Operations of the Cheff of the